Remdesivir Companies
Remdesivir is an antiviral medication developed by the biopharmaceutical company Gilead Sciences. It gained significant attention and use during the COVID-19 pandemic as a potential treatment for severe cases of the disease.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Remdesivir Companies Update
July 2023: Remdesivir is the first antiviral medication that the FDA has licensed for the therapy of COVID-19 among individuals with serious kidney damage, including those on dialysis. Randomized controlled studies, real-world proof, and meta-analyses all indicate the clinical value of COVID-19 in hospitalized patients; nevertheless, due to a lack of data, its usage has historically been restricted in patients with serious kidney disease. The revised prescribing information for patients with renal impairment eliminates the need for estimated glomerular filtration rate (eGFR) testing before and throughout remdesivir treatment. Due to concerns with feasibility, the trial closed earlier than planned, and because enrollment was fewer than anticipated, there was insufficient power to evaluate its efficacy.
Aug 2023: Gilead Sciences announced that it has partnered with Tentarix Biotherapeutics, a privately held company, to research treatments for inflammatory and cancerous conditions. Gilead has agreed to make upfront payments to Tentarix and an equity investment of $66 million. Gilead can purchase up to three of the drug developer's units for $80 million. Through the agreement, Gilead will access Tentarix's exclusive drug development platform for antibody-based treatments that selectively target immune cells associated with the disease without activating other immune cells that could cause unfavorable outcomes.List of Remdesivir Key companies in the market
-
Gilead Sciences, Inc. (US)
-
Mylan (US)
-
Cipla (India)
-
Hetero Labs (India)
-
Jubilant Life Sciences (India)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
